<?xml version="1.0" encoding="UTF-8"?><!-- generator="wordpress/2.0.2" -->
<rss version="0.92">
<channel>
	<title>Bio Screening Industry News</title>
	<link>http://www.bioscreening.net</link>
	<description>Selected Bio Screening news, events and internet recources.</description>
	<lastBuildDate>Wed, 07 May 2008 21:30:37 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform</title>
		<description><![CDATA[Munich and Freiburg, Germany, May 7, 2008 / b3c newswire / – CRELUX and ProQinase announced today that they have entered into a joint agreement to supply customers with crystal-grade protein kinases and readily available kinase complex structures.
Under the agreement, CRELUX and ProQinase will establish and continuously expand an off-the-shelf crystal-grade protein kinase portfolio, optimized [...]]]></description>
		<link>http://www.bioscreening.net/2008/05/07/crelux-and-proqinase-establish-joint-crystal-grade-kinase-protein-and-structures-platform/</link>
			</item>
	<item>
		<title>Invitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe</title>
		<description><![CDATA[Carlsbad, Calif., and Beltsville, Md., May 7, 2008 – In research demonstrating that RNA previously thought to have no biological relevance may be of use for therapeutic and diagnostic targets, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BioServe, the leading provider of clinically annotated tissue samples [...]]]></description>
		<link>http://www.bioscreening.net/2008/05/07/invitrogen-scientists-link-microrna-sequences-to-cancer-using-rna-samples-from-bioserve/</link>
			</item>
	<item>
		<title>Validated biomarkers will drive personalized medicine</title>
		<description><![CDATA[Biomarkers will be accepted as predicted tools, but their clinical usefulness needs to be understood
first, according to personalized medicine expert.
Coordinating personalized medicine on an international level, Dr Edward Abrahams, Executive
Director of the Personalized Medicine Coalition believes that biomarkers will eventually impact all
disease areas.
“When they were validated, and when it can be understood how clinically useful [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/30/validated-biomarkers-will-drive-personalized-medicine/</link>
			</item>
	<item>
		<title>BIO-Europe Spring(R) 2009 Returns to Milan, Italy</title>
		<description><![CDATA[Conference Returns to  Location of its Inaugural Event on March 16-19,  2009
Carlsbad, USA and Madrid,  Spain, April 9, 2008 – Coming on the heels of BIO-Europe Spring 2008 in Madrid  where delegates engaged in an incredible 5800 one-to-one meetings, EBD Group  today announced that the third annual BIO-Europe Spring 2009 [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/30/bio-europe-springr-2009-returns-to-milan-italy/</link>
			</item>
	<item>
		<title>Seegene Multi-Pathogen Detection Tests Now Compatible with Lab901 ScreenTape and Caliper LC90 Automated Detection Systems</title>
		<description><![CDATA[Rockville, MD, April 23, 2008: Seegene today announced that its Seeplex(R) multi-pathogen tests are now optimized for Lab 901&#8217;s ScreenTape(R)  and Caliper LifeSciences’ LC90(R)  automated detection systems. Compatibility with these two leading detection systems opens the way for Seeplex tests to be used throughout a wide spectrum of labs, from small to mid-sized labs to [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/30/seegene-multi-pathogen-detection-tests-now-compatible-with-lab901-screentape-and-caliper-lc90-automated-detection-systems/</link>
			</item>
	<item>
		<title>CLC bio to collaborate with Microsoft on integrating life science technology</title>
		<description><![CDATA[Boston, USA &#8212; April 29, 2008 &#8212; Today at the Bio-IT World Conference &#038; Expo in Boston, USA, CLC bio announced collaboration with Microsoft Corp. on integrating CLC bio&#8217;s extensive bioinformatics solutions with Microsoft&#8217;s software platform, for the benefit of companies, corporations, and institutions in the biotech, pharmaceutical, and life science sectors. CLC bio has [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/30/clc-bio-to-collaborate-with-microsoft-on-integrating-life-science-technology/</link>
			</item>
	<item>
		<title>Mumie - Description and Origin</title>
		<description><![CDATA[Though Mumie has been used in folk medicine of different countries for almost two thousand years, there are still many legends regarding its mysterious origin. In Russia serious research has been conducted on Mumie since 1910. This research became even more intense during the past twenty years Government financing supported research that was conducted at [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/25/mumie-description-and-origin/</link>
			</item>
	<item>
		<title>World Premiere of Next Generation Sequencing solution from CLC bio</title>
		<description><![CDATA[Boston, USA &#8212; April 25, 2008 &#8212; On Monday, April 28, CLC bio will officially unveil their new Next Generation Sequencing solution, CLC Genomics Workbench, the first comprehensive analysis package which can analyze and visualize data from all the major Next Generation Sequencing (NGS) platforms, such as SOLiD from Applied Biosystems, 454 GS flx from [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/25/world-premiere-of-next-generation-sequencing-solution-from-clc-bio/</link>
			</item>
	<item>
		<title>When extractions go toxic</title>
		<description><![CDATA[By extracting information from a freely-available chemical database, Italian forensic scientists have come up with a simple but highly effective method for identifying unknown toxicological compounds in biological samples.
A central component of forensic analysis and drug testing, toxicological analyses of biological samples have traditionally been conducted using gas chromatography/mass spectrometry (GC/MS), with compounds identified by [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/21/when-extractions-go-toxic-when-extractions-go-toxic/</link>
			</item>
	<item>
		<title>Chelsea Therapeutics Gains Global Rights to I-3D Portfolio Targeting Autoimmune Disease and Transplant Rejection</title>
		<description><![CDATA[CHARLOTTE, N.C., April 8, 2008 (PRIME NEWSWIRE) &#8212; Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has acquired full global rights to the I-3D portfolio of orally active, dihydroorotate dehydrogenase (DHODH) inhibiting compounds for the treatment of autoimmune diseases and transplant rejection.


&#160;


Following a decision to focus its resources on its immunomodulatory compounds, Active Biotech AB [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/21/chelsea-therapeutics-gains-global-rights-to-i-3d-portfolio-targeting-autoimmune-disease-and-transplant-rejection/</link>
			</item>
	<item>
		<title>Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec</title>
		<description><![CDATA[Hamburg, Germany &#124; Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that the Company and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a new drug discovery agreement targeting a protease chosen by Ono.
The collaboration applies Evotec&#8217;s proprietary fragment-based drug discovery platform, EVOlutionTM to identify novel, small molecular weight compounds active against a [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/09/ono-enters-into-a-new-fragment-based-drug-discovery-agreement-with-evotec/</link>
			</item>
	<item>
		<title>Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery</title>
		<description><![CDATA[Hamburg, Germany &#124; Oxford, UK &#124; Oslo, Norway - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that Spermatech A/S has chosen them as a partner to identify small molecule therapeutics for their pharmaceutical discovery project.
Through the study of the physiology of sperm motility, more specifically of &#8220;rapid swimmers&#8221; that cause fertilisation, Spermatech have identified [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/09/spermatech-selects-evotec-as-partner-for-high-throughput-screening-and-lead-discovery-2/</link>
			</item>
	<item>
		<title>FDA Issues Public Health Advisory on Chantix</title>
		<description><![CDATA[The U.S. Food and Drug Administration (FDA) today issued a Public Health Advisory to alert health care providers, patients, and caregivers to new safety warnings concerning Chantix (varenicline), a prescription medication used to help patients stop smoking.
On Nov. 20, 2007, FDA issued an Early Communication to the public and health care providers that the agency [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/09/fda-issues-public-health-advisory-on-chantix/</link>
			</item>
	<item>
		<title>Health Care&#8217;s Silent Spring</title>
		<description><![CDATA[As the Intergovernmental Working Group (IGWG) of the WHO prepares to meet and discuss how to best facilitate the expropriation of intellectual property rights (in this case the IPR of pharmaceutical patents) it&#8217;s important to consider the unintended consequences &#8212; the death of medical innovation.
The global purloiners of patents &#8212; led by Jamie Love &#8212; [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/09/health-cares-silent-spring/</link>
			</item>
	<item>
		<title>BIO Spent $6.6 Million on Lobbying Efforts in 2007</title>
		<description><![CDATA[The Biotech Industry Organization (&#8221;BIO&#8221;) spent $6.6 Million on lobbying efforts in 2007, reported the Associated Press.
BIO&#8217;s lobbying efforts last year addressed a range of issues from patent reform to generics to FDA-related issues.  The Associated Press reported as follows:
[BIO&#8217;s] lobbying efforts went toward cloning issues ahead of the Food and Drug Administration&#8217;s ruling [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/09/bio-spent-66-million-on-lobbying-efforts-in-2007/</link>
			</item>
	<item>
		<title>Soon-to-be Laid Off Schering-Plough Employees</title>
		<description><![CDATA[As reported in today&#8217;s Newark Star-Ledger, Schering-Plough&#8217;s New Jersey employees will bear the brunt of Fred Hassan&#8217;s plan to fire, terminate, let go with extreme prejudice, 5,500 people in S-P&#8217;s workforce:
&#8220;Schering-Plough&#8217;s chief executive said yesterday the budget ax will fall first and hardest in New Jersey as the drugmaker cuts more than $1 billion in [...]]]></description>
		<link>http://www.bioscreening.net/2008/04/04/soon-to-be-laid-off-schering-plough-employees/</link>
			</item>
	<item>
		<title>Advances in Cell Based Assays Offer Promise for the Discovery of New Drug Candidates</title>
		<description><![CDATA[LONDON&#8211;(BUSINESS WIRE)&#8211;The drug discovery process has changed dramatically over the past decade        and continues to evolve in response to new discoveries and technologies.        There is also increasing demand to produce more drug candidates and        [...]]]></description>
		<link>http://www.bioscreening.net/2008/03/26/advances-in-cell-based-assays-offer-promise-for-the-discovery-of-new-drug-candidates/</link>
			</item>
	<item>
		<title>Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery</title>
		<description><![CDATA[HAMBURG, Germany and OXFORD, England and OSLO, March 12, 2008 /PRNewswire-FirstCall/ &#8212; Evotec AG announced today that Spermatech A/S has chosen them as a partner to identify small molecule therapeutics for their pharmaceutical discovery project.
Through the study of the physiology of sperm motility, more specifically of &#8220;rapid swimmers&#8221; that cause fertilisation, Spermatech have identified biological [...]]]></description>
		<link>http://www.bioscreening.net/2008/03/18/spermatech-selects-evotec-as-partner-for-high-throughput-screening-and-lead-discovery/</link>
			</item>
	<item>
		<title>Roche deal tests drug cardiotoxicity on unique lab platform</title>
		<description><![CDATA[Roche has entered into an agreement to provide drug compounds for cardiotoxicity testing using a cell-based platform that could play a major role in the preclinical safety evaluation of drugs and newly developed compounds.
The deal aims to detect any drug-induced changes in the electrical activity of the heart, such as prolongation of the QT interval, [...]]]></description>
		<link>http://www.bioscreening.net/2008/03/12/roche-deal-tests-drug-cardiotoxicity-on-unique-lab-platform/</link>
			</item>
	<item>
		<title>CLC bio and University of Copenhagen Sign Site License Agreement</title>
		<description><![CDATA[Copenhagen &#038; Aarhus Denmark, March 11, 2007 &#8212; CLC bio and Department of Biology, Faculty of Science at University of Copenhagen, have signed a site license agreement for CLC bio&#8217;s premier bioinformatics software solution, CLC Combined Workbench, in combination with CLC bio&#8217;s Educational Suite. The deal runs for five years and is for several hundred [...]]]></description>
		<link>http://www.bioscreening.net/2008/03/11/clc-bio-and-university-of-copenhagen-sign-site-license-agreement/</link>
			</item>
</channel>
</rss>
